80 related articles for article (PubMed ID: 21447926)
1. Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties.
Allen MR
Curr Osteoporos Rep; 2018 Apr; 16(2):198-204. PubMed ID: 29497927
[TBL] [Abstract][Full Text] [Related]
2. Towards understanding how bisphosphonate-dependent alterations to nutrient canal integrity can contribute to risk for atypical femoral fractures: Biomechanical considerations and potential relationship to a real-world analogy.
Hart DA
Bioessays; 2024 Feb; 46(2):e2300117. PubMed ID: 38059881
[TBL] [Abstract][Full Text] [Related]
3. Is there genetic susceptibility for atypical femoral fractures?
Ellacott M; Bilgehan Çevik H; Giannoudis PV
Injury; 2024 Feb; 55(2):111312. PubMed ID: 38199157
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites.
Shi S; Duan H; Ou X
Biomed Pharmacother; 2024 Jun; 175():116699. PubMed ID: 38705129
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategy for atypical ulnar fracture in long use of bisphosphonate: A systematic review.
Hirokawa T; Zukawa M; Makino H; Osada R; Kawaguchi Y
J Orthop Sci; 2024 May; 29(3):880-884. PubMed ID: 37032267
[TBL] [Abstract][Full Text] [Related]
6. Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain.
Ota S; Tokizaki T; Sugimoto M; Ochiai R; Haruyama T; Ishihara M; Natsume M; Fukasawa Y; Sakamoto T; Tanzawa S; Usui R; Honda T; Ichikawa Y; Watanabe K; Kawano H; Seki N
Intern Med; 2020 Mar; 59(6):855-857. PubMed ID: 31761883
[TBL] [Abstract][Full Text] [Related]
7. [Morphological analysis of bone dynamics and metabolic bone disease. Pathophisiology of Microdamage].
Mori S
Clin Calcium; 2011 Apr; 21(4):559-65. PubMed ID: 21447923
[TBL] [Abstract][Full Text] [Related]
8. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
Mashiba T
Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
[TBL] [Abstract][Full Text] [Related]
9. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
Soen S
Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
[TBL] [Abstract][Full Text] [Related]
10. [SSBT (severely suppressed bone turnover) ].
Mori S
Clin Calcium; 2013 Mar; 23(3):365-70. PubMed ID: 23445889
[TBL] [Abstract][Full Text] [Related]
11. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
12. Bone Formation Parameters of the Biopsied Ilium Differ between Subtrochanteric and Diaphyseal Atypical Femoral Fractures in Bisphosphonate-Treated Patients.
Kondo N; Fukuhara T; Watanabe Y; Miyasaka D; Yamamoto N; Sato H; Wada Y; Nakatsue T; Fujisawa J; Sakuma M; Imai N; Yoda T; Narita I; Endo N
Tohoku J Exp Med; 2017 Dec; 243(4):247-254. PubMed ID: 29212985
[TBL] [Abstract][Full Text] [Related]
13. [Morphological analysis of bone dynamics and metabolic bone disease. Does bisphosphonate treatment cause severely suppressed bone turnover (SSBT) ?].
Kondo N; Yoda T
Clin Calcium; 2011 Apr; 21(4):583-7. PubMed ID: 21447926
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
